As the Bank of Canada navigates a period of economic uncertainty with potential rate cuts on the horizon, investors are keenly observing how these changes might influence growth sectors within the Canadian market. In such an environment, companies with high insider ownership can be particularly attractive as they often signal strong confidence from those who know the business best.
Top 10 Growth Companies With High Insider Ownership In Canada
| Name | Insider Ownership | Earnings Growth |
| Zedcor (TSXV:ZDC) | 21.1% | 87.6% |
| Robex Resources (TSXV:RBX) | 23.2% | 99.4% |
| Propel Holdings (TSX:PRL) | 36.7% | 31.8% |
| PowerBank (NEOE:SUNN) | 16.1% | 52.1% |
| First National Financial (TSX:FN) | 38.4% | 22.1% |
| Enterprise Group (TSX:E) | 32.1% | 30.4% |
| Discovery Silver (TSX:DSV) | 13.6% | 57.8% |
| Colliers International Group (TSX:CIGI) | 14.0% | 27.2% |
| CEMATRIX (TSX:CEMX) | 10.5% | 76.6% |
| Aritzia (TSX:ATZ) | 17.2% | 29.6% |
Below we spotlight a couple of our favorites from our exclusive screener.
Canfor (TSX:CFP)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Canfor Corporation is an integrated forest products company with operations in the United States, Asia, Canada, Europe, and internationally, and has a market cap of CA$1.57 billion.
Operations: The company's revenue segments consist of Lumber at CA$4.66 billion and Pulp & Paper at CA$730.40 million.
Insider Ownership: 22.8%
Earnings Growth Forecast: 75% p.a.
Canfor's insider ownership reflects confidence, with more shares bought than sold recently. Despite a net loss of C$202.8 million in Q2 2025, revenue growth is expected to outpace the Canadian market at 5% annually. The company is forecasted to achieve profitability within three years, with earnings projected to grow by 75% per year. Recent downsizing actions include closing two U.S. sawmills due to weak market conditions, impacting production capacity and workforce significantly.
- Click here to discover the nuances of Canfor with our detailed analytical future growth report.
- Our expertly prepared valuation report Canfor implies its share price may be lower than expected.
Knight Therapeutics (TSX:GUD)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Knight Therapeutics Inc. is engaged in acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products across Canada and Latin America with a market cap of CA$651.73 million.
Operations: The company's revenue segment is primarily derived from pharmaceuticals, totaling CA$384.56 million.
Insider Ownership: 22.8%
Earnings Growth Forecast: 57.1% p.a.
Knight Therapeutics shows potential with its forecasted revenue growth of 8.4% annually, surpassing the Canadian market's average. Despite recent net losses, earnings are expected to grow significantly at 57.1% per year, indicating strong future profitability prospects. The company has initiated a share buyback program and raised its earnings guidance for 2025 due to better-than-expected performance and strategic acquisitions like Sumitomo products, bolstering its growth strategy in Canada and Latin America.
- Take a closer look at Knight Therapeutics' potential here in our earnings growth report.
- Our comprehensive valuation report raises the possibility that Knight Therapeutics is priced lower than what may be justified by its financials.
Zedcor (TSXV:ZDC)
Simply Wall St Growth Rating: ★★★★★★
Overview: Zedcor Inc. offers turnkey and customized mobile surveillance and live monitoring solutions in Canada and the United States, with a market cap of CA$447.35 million.
Operations: The company generates revenue from its Security & Surveillance segment, amounting to CA$44.50 million.
Insider Ownership: 21.1%
Earnings Growth Forecast: 87.6% p.a.
Zedcor demonstrates strong growth potential with its revenue expected to increase by 35.1% annually, outpacing the Canadian market. Despite recent dilution, earnings are forecast to grow significantly at 87.6% per year. Recent earnings reports show substantial sales growth but a decline in net income for Q2 2025 compared to the previous year, highlighting challenges in profitability despite robust revenue expansion. The stock is trading well below its estimated fair value, suggesting potential undervaluation.
- Unlock comprehensive insights into our analysis of Zedcor stock in this growth report.
- Upon reviewing our latest valuation report, Zedcor's share price might be too pessimistic.
Where To Now?
- Reveal the 43 hidden gems among our Fast Growing TSX Companies With High Insider Ownership screener with a single click here.
- Ready To Venture Into Other Investment Styles? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Knight Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com